|
|
|
Oblique Therapeutics and Targovax enter collaboration to target mutant RAS cancers by combining their ONCOS and Abiprot™ platforms
Dr. Sreesha P Srinivasa, Ph.D., Senior Vice President, Translational R&D Oblique Therapeutics, commented, "We are delighted to partner with Targovax in extending the capabilities of our proprietary AbiprotTM platform to translate antibodies against difficult to reach intra-cellular targets into effective therapeutics. RAS is one of the most frequently mutated oncogenes but has until recently proven to be therapeutically intractable. Oblique has used its AbiprotTM platform to identify novel epitopes on mutant RAS and developed functional antibodies against these epitopes. The ONCOS platform potentially offers an efficient vehicle for intracellular delivery of these functional antibodies into cancer cells. If proven successful, this extends the target space addressable by antibodies to a large number of very important intracellular oncogenes"
|
|
G1 Therapeutics and Boehringer Ingelheim to co-promote trilaciclib in the United States and Puerto Rico
“We believe that trilaciclib has the potential to benefit patients with cancer being treated with chemotherapy across a broad range of solid tumors,” said Mark Velleca, M.D., Ph.D., Chief Executive Officer of G1. “Our clinical trials of trilaciclib in small cell lung cancer have demonstrated significant myelopreservation benefits, and we are excited to collaborate with Boehringer Ingelheim’s experienced commercial oncology team to bring this innovative therapy to patients with SCLC. In addition, this capital efficient launch structure provides us with the ability to make investments in a robust development program to assess trilaciclib in other solid tumors, including colorectal cancer and breast cancer.”
|
Ipsen, Exelixis & Roche to conduct Ph 3 CONTACT-01 (cabozantinib + atezolizumab in mNSCLC) and CONTACT-02 trial (of cabozantinib + atezolizumab in mCRPC) patients
“There is a growing body of preclinical and clinical evidence that cabozantinib may positively impact treatment when paired with immunotherapy,” said Dr. Howard Mayer, Executive Vice President and Head of Research and Development at Ipsen. “We are pleased to enter into this collaboration with Exelixis and Roche to build on the promising data from COSMIC-021 and further examine the potential of cabozantinib in combination with atezolizumab to treat metastatic non-small cell lung cancer and for men with metastatic castration-resistant prostate cancer.”
|
|
PharmaMar receives $100 million from Jazz Pharmaceuticals for the approval of ZepzelcaTM (lurbinectedin) in the U.S.
- PharmaMar could receive up to an additional US $150 million when full approval is achieved.
- Lurbinectedin was approved in the USA last month for the treatment of adult mSCLC patients with disease progression.
- Jazz Pharmaceuticals to launch ZepzelcaTM in the U.S. in July 2020.
|
|
|
Boehringer Ingelheim invests $507.9 million in an External Innovation Hub in China
As announced on July 2nd 2020, Boehringer Ingelheim (BI, Germany) has invested in the creation of an External Innovations hub in China, with the aim of tapping into China’s innovation, research and development opportunities. The company plans on collaborating both by exchange of business development personnel as well as by allowing Chinese academic and biotech institutions access to the Boehringer Ingelheim Venture Fund. BI’s Research Beyond Borders (RBB), Boehringer Ingelheim Venture Fund (BIVF) and Business Development & Licensing (BD&L) arms will be functioning in the new venture.
The new External innovations hub will be built in a span of 5 years. The team at the hub is aiming to achieve 71 approvals in China, either in the form of new products or indication, by the year 2023.
“This innovative business model will provide one-stop shop solutions for innovators in the biopharmaceutical industry in China and Asia by providing access to early stage research collaborations, strategic partnerships across the value chain as well as equity investment to help convert their creative ideas into reality.”- Dr. Weiyi Zhang, Head of Boehringer Ingelheim External Innovation Hub China.
|
|
Freeline Therapeutics bags $120 million in series C funding for its AAV based Haemophilia B gene therapy program
Freeline Therapeutics (Freeline, London) announced securing $120 million in series C funding for its proprietary AAV based gene therapy for Haemophila A&B, Fabry Disease and Gaucher Disease. The investment round was led by Syncona that put in $40 million followed by $80 million investment by Novo Holdings A/S, Eventide Asset Management Wellington Management Company, Cowen Healthcare Investments, Acorn Bioventures and Ample Plus Fund. The announcement came in on 30th June 2020.
Freeline’s AAV gene therapy platform consists of viral capsid-borne cell specificity for targeted delivery of the therapeutic protein expression cassette. Their technology allows for high protein expression levels per transduced viral genome, thereby maintaining low viral titers for efficient gene delivery.
The company plans to use the secured funds towards advancing its lead Haemophilia B program into Phase III clinical trial, while pushing its Fabry’s Disease program through Phase 1/2. The money will also be used to advance the Haemophilia A and Gaucher’s Disease programs past preclinical stages.
|
|
Click Here for more news and details on mergers, acquisitions and business updates
|
|
|
Disclaimer
The editors take care to share authentic information. In case of any discrepancies please write to medness.newsletter@gmail.com
The sponsors do not have any influence on the nature or kind of the news/analysis reported in MedNess. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of Medness. Examples of analysis performed within this article are only examples. They should not be utilized in real-world analytic products as they are based only on very limited and dated open source information. Assumptions made within the analysis are not reflective of the position of anyone volunteering or working for Medness. This blog is strictly for news and information. It does not provide medical advice, diagnosis or treatment nor investment suggestions. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or another qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.
|
|
|
|
|
|
|